{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-096656","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2025-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.354815+00:00","generated_at":"2026-05-18T05:54:32.185536+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Alaunos Therapeutics appoints Michael A. Jerman as director, effective July 15, 2025","bullets":["Jerman fills vacancy from Dale Curtis Hogue's resignation; also joins Audit and Compensation Committees.","Jerman replaces Holger Weis on committees after Weis became CEO; Jerman will chair Audit Committee.","Compensation: $40k annual cash retainer, plus committee fees; initial option for 10,000 shares vesting over 36 months.","Prorated annual grant of 3,200 shares awarded; vesting subject to continued service through 2026 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-096656","json":"https://secwatch.observer/filing/0000950170-25-096656.json","markdown":"https://secwatch.observer/filing/0000950170-25-096656.md","text":"https://secwatch.observer/filing/0000950170-25-096656.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000095017025096656/0000950170-25-096656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000095017025096656/tcrt-20250715.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:54:32.185536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}